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Introduction 
Dupilumab, a biologic agent approved in March 
2017, is a monoclonal antibody developed to target 
the IL4Rα subunit of IL4 and IL13. Dupilumab is the 
first biologic agent to demonstrate efficacy in 
treating moderate to severe refractory atopic 
dermatitis [1, 2]. We report a patient who 
experienced erythroderma shortly after the initiation 
of dupilumab for atopic dermatitis. After further 
blood testing, he was diagnosed with Sézary 
syndrome (SS). To our knowledge, this is the first case 
of SS developing following the administration of 
dupilumab. 
 
Case Synopsis 
A 64-year-old man with a history of refractory adult-
onset atopic dermatitis diagnosed in 2014, 
presented to MD Anderson Cancer Center in 
September 2019 with a three-month history of 
erythroderma. Since 2017, he experienced 
continued progression of atopic dermatitis despite 
the use of topical corticosteroids and ultraviolet light 
therapy. In June 2019, the patient was initiated on 
subcutaneous dupilumab. Two weeks after a 600mg 
loading dose of dupilumab, he presented with an 
erythrodermic rash covering 95% of his body surface 
area. He subsequently received methylprednisolone 
which resulted in improvement of the erythroderma. 
However, the erythroderma returned as the 
corticosteroids were tapered. The patient remained 
on dupilumab for four subsequent injections during 
which time he experienced progression of the 
erythroderma. 
A punch biopsy of a left abdominal plaque was 
performed at this time. Pathology demonstrated 
psoriasiform epidermal hyperplasia, hypogranulosis, 
neutrophils within the epidermis, and a superficial 
perivascular lymphohistiocytic infiltrate. 
Lymphocytic exocytosis was also present with some 
small intraepidermal lymphocytes showing 
convoluted nuclear contours. Despite the presence 
of atypical lymphocytes, the patient was diagnosed 
with psoriasis. He was prescribed guselkumab 
100mg/mL for one month, cyclosporine 200mg 
taper for two months, and topical steroids. Despite 
these treatments, the patient had persistent 
erythroderma and lymphadenopathy. 
In the setting of persistent erythroderma, flow 
cytometry was performed in September 2019 to rule 
out SS. Results showed a markedly increased CD4 to 
CD8 ratio of 43:1. Atypical CD4+ T-lymphocytes were 
significantly increased in number and demonstrated 
partial loss of CD7 expression. T-cell receptor (TCR) 
gene rearrangement studies were also performed, 
revealing monoclonal TCR-gamma gene 
Abstract 
Dupilumab is a monoclonal antibody that inhibits 
interleukin-4 and interleukin-13 signaling. It is the 
first biologic agent to demonstrate efficacy in 
treating moderate-to-severe refractory atopic 
dermatitis [1, 2]. Although dupilumab provides 
promise for the treatment of atopic and allergic 
conditions, clinicians should take into account its 
novelty and the potential for unexpected adverse 
events. We present a patient who developed Sézary 
syndrome following the initiation of dupilumab. 
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rearrangements and polyclonal TCR-beta gene 
rearrangements in both the skin and blood. Given 
these immunophenotypic findings in the setting of 
erythroderma, the patient was diagnosed with SS. 
The patient was subsequently referred to MD 
Anderson Cancer Center for further workup and 
management of SS. He presented clinically with mild 
pruritus, a severe burning sensation, and erythema 
and exfoliation involving 49% of his total BSA. 
Physical examination also revealed hyperkeratotic 
palmar and plantar surfaces, scaling of the bilateral 
toes, and mild bilateral ectropion. Flow cytometry 
performed at this time revealed over 7,000 
CD4+CD26- Sezary cells/mm3. Given the 
combination of clinical and laboratory findings, the 
diagnosis of SS was confirmed. 
The patient was initiated on oral bexarotene 300mg 
and biweekly extracorporeal photopheresis. He also 
continued to apply topical desoximetasone to the 
affected areas. 
 
Case Discussion 
Dupilumab has proven to be an effective treatment 
for refractory atopic dermatitis since its approval by 
the Food and Drug Administration in 2017 [1]. 
Dupilumab is a human monoclonal IgG antibody 
that binds to the IL4 receptor, thus inhibiting the 
actions of IL4 and IL13 [1]. This inhibition of IL4 and 
IL13 leads to decreased cytokine-induced 
inflammatory responses, ultimately dampening the 
Th2 response and minimizing the disease activity of 
atopic dermatitis [1]. Phase III clinical trials studying 
the efficacy of dupilumab for atopic dermatitis 
demonstrated appreciable improvement in 
refractory atopic dermatitis [1]. In all three clinical 
trials, response to dupilumab (~37%) was markedly 
higher than those receiving placebo (~10%), [1]. 
Although dupilumab has demonstrated efficacy in 
the treatment of atopic and allergic conditions, 
unexpected events have been reported following its 
use, including conjunctivitis and alopecia areata [3, 
4]. To our knowledge, this is the first report of a 
patient diagnosed with SS following the initiation of 
dupilumab. 
Sézary syndrome is associated with a TH2 response 
[5]. In SS, both malignant Sezary cells and benign 
reactionary cells have been shown to have a TH2 
predominance of cytokines such as IL4, IL5, IL10, and 
IL13 [5]. Dupilumab’s effect of inhibiting the TH2 
response suggests that it would combat the 
progression of SS via a reduction of atypical 
lymphocytic proliferation. Therefore, the 
development of SS in the patient in this case is 
unexpected. 
The temporal relationship between the initiation of 
dupilumab and the onset of erythroderma suggests 
that dupilumab was a trigger for SS in this patient. 
Dupilumab has been previously reported to have 
caused an exacerbation of erythematous lesions in a 
patient with mycosis fungoides [6]. Chiba et al. (2019) 
describes a patient who was initially misdiagnosed 
with atopic dermatitis and prescribed dupilumab 
injections. However, the use of dupilumab caused a 
flare of the skin lesions. Owing to the progression of 
disease, a skin biopsy was performed and confirmed 
the diagnosis of mycosis fungoides. 
Alternatively, our patient may have had mycosis 
fungoides which was initially misdiagnosed as adult-
onset atopic dermatitis. The exacerbation of skin 
lesions in the patient described by Chiba et al. (2019) 
and the case described in this report following the 
use of dupilumab suggests that dupilumab may 
trigger or promote the development of cutaneous T-
cell lymphoma (CTCL) in certain patients. 
Sézary syndrome is an uncommon and aggressive 
primary CTCL characterized by pruritic 
erythroderma, lymphadenopathy, and atypical 
circulating lymphocytes. The pathogenesis of SS is 
only partially understood. Circulating neoplastic T 
cells in SS have a central memory T-cell phenotype 
and are capable of circulating between the skin, 
lymph nodes, and blood [7]. Moreover, certain 
human leukocyte antigen alleles are associated with 
CTCL, suggesting that a pathogenic mechanism may 
involve inappropriate T-cell activation via antigen 
presentation and subsequent expansion of the 
aberrant T-cell population [8]. This combined 
knowledge suggests that the existence of an 
external trigger or disease-promoting factor  
Volume 26 Number 4| April 2020| 
26(4):17 
 
 
- 3 - 
Dermatology Online Journal  ||  Letter 
contributes to the development of SS [9]. Multiple 
infections, medications, and occupational causes 
have been investigated as triggers or promoters of 
CTCL, including hydrochlorothiazide diuretics, 
Staphylococcus aureus, Chlamydia pneumoniae, 
dermatophytes, human T-Cell lymphotropic virus 
type 1, Epstein-Barr virus, and herpes simplex virus 
[10].  We propose that the dupilumab-induced 
alteration in cytokines and phenotypic expression of 
lymphocytes could be an inciting factor for the 
development or exacerbation of SS in certain 
patients, as in this case. Further investigation is 
warranted regarding the inhibition of IL4 and IL13 
and the development of SS. 
 
Conclusion 
We report, to our knowledge, the first case of SS 
developing in association with administration of 
dupilumab. Given the aggressive nature of SS, 
clinicians should be aware of this association for 
prompt diagnosis and treatment. Although 
dupilumab provides promise in the treatment of 
atopic and allergic conditions, clinicians should take 
into account its novelty and the potential for 
unexpected adverse events. 
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